Eurofins issues EUR 500m new Euro bond

Eurofins Scientific (ERF FP, unrated), the global leader in bioanalytical testing, announces that it has successfully raised EUR 500m in its latest senior unsecured Euro bond public issuance. The bonds have a 7.5-year maturity (due 30 January 2023) and will bear an annual rate of 3.375% (ACT/ACT). The issue was more than 2x times over-subscribed.

Eurofins intends to use the proceeds of the issuance for general corporate purposes, including refinancing some of its existing debt instruments, as well as to fund any further growth opportunity in-line with the Group's strategy and objectives. The new bond further improves Eurofins' liquidity position by lengthening its debt maturity profile.

Comment from Dr. Gilles Martin, Eurofins CEO:"I am pleased with the result of our latest public bond issuance. In light of the market volatility due to the developments in certain geographies, specifically in Greece and China, we have decided to further optimize our funding position to lengthen our financing maturity, to secure the refinancing of our instruments coming due in the next couple of years, and more generally to secure our ability to respond to compelling opportunities while maintaining a strong balance sheet structure."

BNP Paribas, HSBC and SG CIB acted as joint bookrunners for the transaction.

The bonds will be listed from their issue date (30 July 2015) on the regulated market of the Luxembourg stock exchange (ISIN XS1268496640). The bonds are not registered under the US Securities Act of 1933 as amended (the "Securities Act"), and may not be offered or sold in the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration.

For more information please visit or contact:

Notes for the editor:

Eurofins - a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services.

With over 17,000 staff in more than 200 laboratories across 36 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.